Tradjenta: Phase III data

A Phase III trial in 241 Type II diabetics aged >=70 years inadequately controlled with metformin and/or sulfonylurea and/or insulin showed that once-daily 5 mg Tradjenta as an add-on therapy significantly reduced mean HbA1c from baseline to week 24 vs. placebo (placebo-adjusted reduction of 0.64%, p<0.0001). Hypoglycemia occurred in 24.1% of patients receiving Tradjenta vs. 16.5% for placebo (p=0.1625). Data were presented at the American Diabetes Association meeting in Philadelphia. ...